Interpretation of the Role of Germline and Somatic Non-coding Mutations in Cancer: Expression and Chromatin Conformation Informed Analysis
Overview
Affiliations
Background: There has been extensive scrutiny of cancer driving mutations within the exome (especially amino acid altering mutations) as these are more likely to have a clear impact on protein functions, and thus on cell biology. However, this has come at the neglect of systematic identification of regulatory (non-coding) variants, which have recently been identified as putative somatic drivers and key germline risk factors for cancer development. Comprehensive understanding of non-coding mutations requires understanding their role in the disruption of regulatory elements, which then disrupt key biological functions such as gene expression.
Main Body: We describe how advancements in sequencing technologies have led to the identification of a large number of non-coding mutations with uncharacterized biological significance. We summarize the strategies that have been developed to interpret and prioritize the biological mechanisms impacted by non-coding mutations, focusing on recent annotation of cancer non-coding variants utilizing chromatin states, eQTLs, and chromatin conformation data.
Conclusion: We believe that a better understanding of how to apply different regulatory data types into the study of non-coding mutations will enhance the discovery of novel mechanisms driving cancer.
Koroglu M, Bilguvar K Methods Mol Biol. 2025; 2889:207-233.
PMID: 39745615 DOI: 10.1007/978-1-0716-4322-8_15.
Arumugam T, Adimulam T, Gokul A, Ramsuran V Front Immunol. 2024; 15:1422834.
PMID: 39355248 PMC: 11442197. DOI: 10.3389/fimmu.2024.1422834.
Iniguez-Munoz S, Llinas-Arias P, Ensenyat-Mendez M, Bedoya-Lopez A, Orozco J, Cortes J Cell Mol Life Sci. 2024; 81(1):274.
PMID: 38902506 PMC: 11335195. DOI: 10.1007/s00018-024-05314-z.
Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research.
Ibrahim M, Flanagan J, Ibrahim T, Rouleau E Future Oncol. 2024; 20(18):1289-1298.
PMID: 38722139 PMC: 11318707. DOI: 10.2217/fon-2023-0665.
Lee H, Ozbulak U, Park H, Depuydt S, De Neve W, Vankerschaver J BMC Bioinformatics. 2024; 25(1):170.
PMID: 38689247 PMC: 11059627. DOI: 10.1186/s12859-024-05787-6.